{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:40:25Z","timestamp":1784086825428,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100018741","name":"Tosoh","doi-asserted-by":"publisher","award":["Tosoh"],"award-info":[{"award-number":["Tosoh"]}],"id":[{"id":"10.13039\/100018741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00277-024-05685-0","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T01:03:18Z","timestamp":1710723798000},"page":"1705-1715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Autotaxin is a potential predictive marker for the development of veno-occlusive disease\/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation"],"prefix":"10.1007","volume":"103","author":[{"given":"Kazuya","family":"Takemura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9200-4804","authenticated-orcid":false,"given":"Mika","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sakatoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Makuuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhito","family":"Takakuwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asao","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutaka","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"5685_CR1","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/nejmc061443","volume":"354","author":"EA Copelan","year":"2006","unstructured":"Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354:1813\u20131826. https:\/\/doi.org\/10.1056\/nejmc061443","journal-title":"N Engl J Med"},{"key":"5685_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/hep.23533","volume":"51","author":"GB McDonald","year":"2010","unstructured":"McDonald GB (2010) Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 51:1450\u20131460. https:\/\/doi.org\/10.1002\/hep.23533","journal-title":"Hepatology"},{"key":"5685_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2991\/chi.d.190317.001","volume":"1","author":"M Palomo","year":"2019","unstructured":"Palomo M, Diaz-Ricart M, Carreras E (2019) Endothelial dysfunction in hematopoietic cell transplantation. Clin Hematol Int 1:45\u201351. https:\/\/doi.org\/10.2991\/chi.d.190317.001","journal-title":"Clin Hematol Int"},{"key":"5685_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.bbmt.2009.01.013","volume":"15","author":"M Palomo","year":"2009","unstructured":"Palomo M, Diaz-Ricart M, Carbo C et al (2009) The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the Allogeneic setting and involves several pathogenic mechanisms. Biol Blood Marrow Transpl 15:537\u2013546. https:\/\/doi.org\/10.1016\/j.bbmt.2009.01.013","journal-title":"Biol Blood Marrow Transpl"},{"key":"5685_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/bjh.16557","volume":"190","author":"MS Cairo","year":"2020","unstructured":"Cairo MS, Cooke KR, Lazarus HM, Chao N (2020) Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS\/VOD after haematopoietic cell transplantation. Brit J Haematol 190:822\u2013836. https:\/\/doi.org\/10.1111\/bjh.16557","journal-title":"Brit J Haematol"},{"key":"5685_CR6","doi-asserted-by":"publisher","unstructured":"Mohty M, Malard F, Abecassis M, et al (2016) Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 51:906\u2013912. https:\/\/doi.org\/10.1038\/bmt.2016.130.","DOI":"10.1038\/bmt.2016.130"},{"key":"5685_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/hep.1840040121","volume":"4","author":"GB Mcdonald","year":"1984","unstructured":"Mcdonald GB, Sharma P, Matthews DE et al (1984) Venocclusive Disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4:116\u2013122. https:\/\/doi.org\/10.1002\/hep.1840040121","journal-title":"Hepatology"},{"key":"5685_CR8","doi-asserted-by":"publisher","unstructured":"Jones RJ, Lee KSK, Beschorner WE et al (1987) Venoocclusive disease of the liver following bone marrow transplantation. Transplant 44:778\u2013783. https:\/\/doi.org\/10.1097\/00007890-198712000-00011","DOI":"10.1097\/00007890-198712000-00011"},{"key":"5685_CR9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/bmt.2016.320","volume":"52","author":"A Colecchia","year":"2017","unstructured":"Colecchia A, Marasco G, Ravaioli F et al (2017) Usefulness of liver stiffness measurement in predicting hepatic veno-occlusive disease development in patients who undergo HSCT. Bone Marrow Transpl 52:494\u2013497. https:\/\/doi.org\/10.1038\/bmt.2016.320","journal-title":"Bone Marrow Transpl"},{"key":"5685_CR10","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.bbmt.2018.05.025","volume":"24","author":"M Nishida","year":"2018","unstructured":"Nishida M, Kahata K, Hayase E et al (2018) Novel Ultrasonographic Scoring System of Sinusoidal obstruction syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 24:1896\u20131900. https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.025","journal-title":"Biol Blood Marrow Transpl"},{"key":"5685_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/bmt.2015.283","volume":"51","author":"K Yakushijin","year":"2016","unstructured":"Yakushijin K, Atsuta Y, Doki N et al (2016) Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transpl 51:403\u2013409. https:\/\/doi.org\/10.1038\/bmt.2015.283","journal-title":"Bone Marrow Transpl"},{"key":"5685_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Malard F, Abecassis M et al (2015) Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives\u2014a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl 50:781\u2013789. https:\/\/doi.org\/10.1038\/bmt.2015.52","journal-title":"Bone Marrow Transpl"},{"key":"5685_CR13","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1182\/blood.V89.6.2184","volume":"89","author":"C Salat","year":"1997","unstructured":"Salat C, Holler E, Kolb HJ et al (1997) Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 89:2184\u20132188","journal-title":"Blood"},{"key":"5685_CR14","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1182\/blood.V81.12.3458.3458","volume":"81","author":"EM Faioni","year":"1993","unstructured":"Faioni EM, Krachmalnicoff A, Bearman SI et al (1993) Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood 81:3458\u20133462","journal-title":"Blood"},{"key":"5685_CR15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/sj.bmt.1702624","volume":"26","author":"S Tanikawa","year":"2000","unstructured":"Tanikawa S, Mori S, Ohhashi K et al (2000) Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study. Bone Marrow Transpl 26:881\u2013886. https:\/\/doi.org\/10.1038\/sj.bmt.1702624","journal-title":"Bone Marrow Transpl"},{"key":"5685_CR16","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1016\/S0021-9258(18)45911-X","volume":"267","author":"ML Stracke","year":"1992","unstructured":"Stracke ML, Krutzsch HC, Unsworth EJ et al (1992) Identification, purification, and Partial Sequence Analysis of Autotaxin, a Novel motility-stimulating Protein*. J Biol Chem 267:2524\u20132529","journal-title":"J Biol Chem"},{"key":"5685_CR17","doi-asserted-by":"publisher","first-page":"39436","DOI":"10.1074\/jbc.m205623200","volume":"277","author":"A Tokumura","year":"2002","unstructured":"Tokumura A, Majima E, Kariya Y et al (2002) Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 277:39436\u201339442. https:\/\/doi.org\/10.1074\/jbc.m205623200","journal-title":"J Biol Chem"},{"key":"5685_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1083\/jcb.200206094","volume":"158","author":"WH Moolenaar","year":"2002","unstructured":"Moolenaar WH (2002) Lysophospholipids in the limelight: autotaxin takes center stage. J Cell Biol 158:197\u2013199. https:\/\/doi.org\/10.1083\/jcb.200206094","journal-title":"J Cell Biol"},{"key":"5685_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/jb\/mvu077","volume":"157","author":"S Aikawa","year":"2015","unstructured":"Aikawa S, Hashimoto T, Kano K, Aoki J (2015) Lysophosphatidic acid as a lipid mediator with multiple biological actions. J Biochem 157:81\u201389. https:\/\/doi.org\/10.1093\/jb\/mvu077","journal-title":"J Biochem"},{"key":"5685_CR20","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.clinbiochem.2006.10.009","volume":"40","author":"K Nakamura","year":"2007","unstructured":"Nakamura K, Ohkawa R, Okubo S et al (2007) Measurement of lysophospholipase D\/autotaxin activity in human serum samples. Clin Biochem 40:274\u2013277. https:\/\/doi.org\/10.1016\/j.clinbiochem.2006.10.009","journal-title":"Clin Biochem"},{"key":"5685_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cca.2007.10.005","volume":"388","author":"K Nakamura","year":"2008","unstructured":"Nakamura K, Igarashi K, Ide K et al (2008) Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. Clin Chim Acta 388:51\u201358. https:\/\/doi.org\/10.1016\/j.cca.2007.10.005","journal-title":"Clin Chim Acta"},{"key":"5685_CR22","doi-asserted-by":"publisher","first-page":"46705","DOI":"10.1038\/srep46705","volume":"7","author":"T Yamazaki","year":"2017","unstructured":"Yamazaki T, Joshita S, Umemura T et al (2017) Association of Serum Autotaxin Levels with liver fibrosis in patients with chronic Hepatitis C. Sci Rep 7:46705. https:\/\/doi.org\/10.1038\/srep46705","journal-title":"Sci Rep"},{"key":"5685_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/jgh.15114","volume":"36","author":"K Takemura","year":"2021","unstructured":"Takemura K, Takizawa E, Tamori A et al (2021) Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C. J Gastroenterol Hepatol 36:217\u2013224. https:\/\/doi.org\/10.1111\/jgh.15114","journal-title":"J Gastroenterol Hepatol"},{"key":"5685_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.canlet.2009.04.029","volume":"284","author":"S Jansen","year":"2009","unstructured":"Jansen S, Andries M, Vekemans K et al (2009) Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett 284:216\u2013221. https:\/\/doi.org\/10.1016\/j.canlet.2009.04.029","journal-title":"Cancer Lett"},{"key":"5685_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.bmt.1704329","volume":"33","author":"S Corbacioglu","year":"2004","unstructured":"Corbacioglu S, Greil J, Peters C et al (2004) Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transpl 33:189\u2013195. https:\/\/doi.org\/10.1038\/sj.bmt.1704329","journal-title":"Bone Marrow Transpl"},{"key":"5685_CR26","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D et al (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl 15:1628\u20131633. https:\/\/doi.org\/10.1016\/j.bbmt.2009.07.004","journal-title":"Biol Blood Marrow Transpl"},{"key":"5685_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D et al (2009) Reduced-intensity conditioning Regimen Workshop: defining the dose spectrum. Report of a Workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transpl 15:367\u2013369. https:\/\/doi.org\/10.1016\/j.bbmt.2008.12.497","journal-title":"Biol Blood Marrow Transpl"},{"key":"5685_CR28","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR et al (2014) Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 123:3664\u20133671. https:\/\/doi.org\/10.1182\/blood-2014-01-552984","journal-title":"Blood"},{"key":"5685_CR29","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"key":"5685_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-5926-1-1","volume":"1","author":"F Braet","year":"2002","unstructured":"Braet F, Wisse E (2002) Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 1:1. https:\/\/doi.org\/10.1186\/1476-5926-1-1","journal-title":"Comp Hepatol"},{"key":"5685_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/bjh.13215","volume":"168","author":"E Carreras","year":"2015","unstructured":"Carreras E (2015) How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Brit J Haematol 168:481\u2013491. https:\/\/doi.org\/10.1111\/bjh.13215","journal-title":"Brit J Haematol"},{"key":"5685_CR32","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/s0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Cesaro S, Faraci M et al (2012) Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 379:1301\u20131309. https:\/\/doi.org\/10.1016\/s0140-6736(11)61938-7","journal-title":"Lancet"},{"key":"5685_CR33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.12558","volume":"163","author":"FL Dignan","year":"2013","unstructured":"Dignan FL, Wynn RF, Hadzic N et al (2013) BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Brit J Haematol 163:444\u2013457. https:\/\/doi.org\/10.1111\/bjh.12558","journal-title":"Brit J Haematol"},{"key":"5685_CR34","doi-asserted-by":"publisher","unstructured":"Chalandon Y, Mamez A-C, Giannotti F et al (2022) Defibrotide shows efficacy in the Prevention of Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: a retrospective study. Transpl Cell Ther 28. https:\/\/doi.org\/10.1016\/j.jtct.2022.08.003. :765.e1-765.e9","DOI":"10.1016\/j.jtct.2022.08.003"},{"key":"5685_CR35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40261-022-01140-y","volume":"42","author":"S Corbacioglu","year":"2022","unstructured":"Corbacioglu S, Topaloglu O, Aggarwal S (2022) A systematic review and Meta-analysis of studies of Defibrotide Prophylaxis for Veno-Occlusive Disease\/Sinusoidal obstruction syndrome. Clin Drug Invest 42:465\u2013476. https:\/\/doi.org\/10.1007\/s40261-022-01140-y","journal-title":"Clin Drug Invest"},{"key":"5685_CR36","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.clinbiochem.2011.03.128","volume":"44","author":"Y Nakai","year":"2011","unstructured":"Nakai Y, Ikeda H, Nakamura K et al (2011) Specific increase in serum autotaxin activity in patients with pancreatic cancer. Clin Biochem 44:576\u2013581. https:\/\/doi.org\/10.1016\/j.clinbiochem.2011.03.128","journal-title":"Clin Biochem"},{"key":"5685_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1365-2141.2008.07325.x","volume":"143","author":"A Masuda","year":"2008","unstructured":"Masuda A, Nakamura K, Izutsu K et al (2008) Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br J Haematol 143:60\u201370. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07325.x","journal-title":"Br J Haematol"},{"key":"5685_CR38","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/j.cca.2011.06.039","volume":"412","author":"A Masuda","year":"2011","unstructured":"Masuda A, Fujii T, Iwasawa Y et al (2011) Serum autotaxin measurements in pregnant women: application for the differentiation of normal pregnancy and pregnancy-induced hypertension. Clin Chim Acta 412:1944\u20131950. https:\/\/doi.org\/10.1016\/j.cca.2011.06.039","journal-title":"Clin Chim Acta"},{"key":"5685_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/jb\/mvq052","volume":"148","author":"K Nakanaga","year":"2010","unstructured":"Nakanaga K, Hama K, Aoki J (2010) Autotaxin\u2014an LPA producing enzyme with diverse functions. J Biochem 148:13\u201324. https:\/\/doi.org\/10.1093\/jb\/mvq052","journal-title":"J Biochem"},{"key":"5685_CR40","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1177\/0004563217741509","volume":"55","author":"H Ikeda","year":"2018","unstructured":"Ikeda H, Kobayashi M, Kumada H et al (2018) Performance of autotaxin as a serum marker of liver fibrosis. Ann Clin Biochem 55:469\u2013477","journal-title":"Ann Clin Biochem"},{"key":"5685_CR41","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1096\/fj.15-274480","volume":"29","author":"MGK Benesch","year":"2015","unstructured":"Benesch MGK, Tang X, Dewald J et al (2015) Tumor-induced inflammation in mammary adipose tissue stimulates a vicious cycle of autotaxin expression and breast cancer progression. Faseb J 29:3990\u20134000. https:\/\/doi.org\/10.1096\/fj.15-274480","journal-title":"Faseb J"},{"key":"5685_CR42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cca.2012.10.003","volume":"415","author":"H Sumida","year":"2013","unstructured":"Sumida H, Nakamura K, Yanagida K et al (2013) Decrease in circulating autotaxin by oral administration of prednisolone. Clin Chim Acta 415:74\u201380. https:\/\/doi.org\/10.1016\/j.cca.2012.10.003","journal-title":"Clin Chim Acta"},{"key":"5685_CR43","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","volume":"58","author":"M Mohty","year":"2023","unstructured":"Mohty M, Malard F, Alaskar AS et al (2023) Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT). Bone Marrow Transpl 58:749\u2013754. https:\/\/doi.org\/10.1038\/s41409-023-01992-8","journal-title":"Bone Marrow Transpl"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05685-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05685-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05685-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T06:04:50Z","timestamp":1712901890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05685-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["5685"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05685-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"14 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Osaka City University (the predecessor of Osaka Metropolitan University) Graduate School of Medicine (Approval no. 2020\u2009\u2212\u2009213). This study was conducted in accordance with the ethical principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"According to our ethical guidelines and our institutional ethical committee, consent was obtained using an opt-out approach, where we provided information about the research framework and allowed participants to decline participation, rather than obtaining informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors\u2019 potential conflicts of interest in this research area are listed below. Except for Tosoh Corp., no direct funding was received for this research. No assistance with medical writing or data analysis work was received from the following companies. A patent application is pending for the results of this research from our university and Tosoh Cooperation.\u3000KT, KS, K Ido, AH and H Kubota have no conflicts of interests in this research area; M Nakamae: research funding from Veritas Corp. and honoraria to spouse (Please refer to HN disclosure); HO: research funding from Takeda Pharmaceutical Co., Ltd., and honoraria from Nippon Shinyaku Co., Ltd. and Asahi Kasei Pharma Corp.; YM: honoraria from Asahi Kasei Pharma Corp.; TT: research funding from Pfizer Japan Inc., Janssen Pharmaceutical K.K., and honoraria from Kyowa Kirin Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K. and Janssen Pharmaceutical K.K.; YN: research funding from Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., and Novartis Pharma K.K., and honoraria from Novartis Pharma K.K., Janssen Pharmaceutical K.K., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., and Kyowa Kirin Co., Ltd.; H Koh: research funding from Takeda Pharmaceutical Co., Ltd., and honoraria from Asahi Kasei Pharma Corp. and Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Nippon Shinyaku Co., Ltd., and Sumitomo Pharma Co., Ltd.; M.Nishimoto: research funding from Pfizer Japan Inc., and honoraria from Asahi Kasei Pharma Corp., Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., and Janssen Pharmaceutical K.K.; K Igarashi: Employees of Tosoh Corportion,; MH: research funding from Tosoh Corp., Pfizer Japan Inc., Nippon Shinyaku Co., Ltd., Sekisui Medical Co., Ltd., ARKRAY, Inc. and donation for research from JCR Pharmaceuticals Co., Ltd., Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Asahi Kasei Pharma Corp., Sumitomo Pharma Co., Ltd., and Sekisui Medical Co., Ltd., and honoraria from Asahi Kasei Pharma Corp., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Nippon Kayaku Co., Ltd., Novartis Pharma K.K., Janssen Pharmaceutical K.K., Daiichi Sankyo Co., Ltd., Sumitomo Pharma Co., Ltd.; HN: research funding Novartis Pharma K.K., and Takeda Pharmaceutical Co., Ltd., and honoraria from Astellas Pharma Inc, Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Sumitomo Pharma Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma, and Janssen Pharmaceutical K.K.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}